Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.32 |
| ▸ | MICA | Q29983 | 1/20 | 0.32 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22065471 | 0.87 | TACR1 (0.40) | TACR1PDE2AIDO1TDO2 | |
| SCHEMBL8127537 | 0.83 | PDE2A (0.35) | TACR1SOS1PDE2ACXCR2RXRA | |
| SCHEMBL21216527 | 0.80 | CES2 (0.37) | IDO1TDO2 | |
| SCHEMBL1295467 | 0.80 | TACR1 (0.33) | TACR1SOS1PDE2ACXCR2RXRA | |
| SCHEMBL6819089 | 0.80 | TACR1 (0.43) | TACR1SOS1PDE2AIDO1TDO2 | |
| SCHEMBL25429733 | 0.80 | RXRA (0.35) | TACR1SOS1PDE2ACXCR2RXRA | |
| SCHEMBL16958699 | 0.80 | TACR1 (0.33) | TACR1SOS1PDE2ACXCR2RXRA | |
| SCHEMBL17069190 | 0.80 | PDE2A (0.37) | TACR1SOS1PDE2ACXCR2RXRA | |
| SCHEMBL1295024 | 0.80 | PDE2A (0.41) | TACR1SOS1PDE2ACXCR2RXRA | |
| SCHEMBL4229656 | 0.80 | TACR1 (0.43) | TACR1SOS1PDE2AIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | TACR1 4797/4885SOS1 2299/4885PDE2A 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.